DAC for YCC Sarcoma

Dr Hyo Song Kim
hyosong77@yuhs.ac

Request Access

Dataset ID	Description	Technology	Samples
EGAD50000000114	This study includes an open-label, phase 2 study to determine the activity of the anti-VEGF receptor tyrosine-kinase inhibitor, pazopanib, combined with the anti-PD-L1 immune checkpoint inhibitor, durvalumab, in unselected advanced sarcomas. We conducted whole exome and transcriptomic sequencing with pre-treatment tissue biopsy to correlate clinical outcomes with molecular and genomic biomarkers to identify patients who would most likely benefit from the combination treatment.	Illumina HiSeq 2500	83